EKSO_OUT_1 [2025-04-28 19:06:53 -0400] 4878 Bytes | 1455 tokens | Cum: 1455 tkns (18.19% of 8k)
==========================================================================

Captain's log, 7:06 PM on Mon Apr 28, 2025. Target in sight: Ekso Bionics (EKSO), moving from $0.4420 to $0.5195. Risk: acceptable. Opportunity: unknown. We proceed to analysis.

--- COMPANY PROFILE ---
Company: Ekso Bionics (EKSO)
IPO: IPO date unknown
Shares Outstanding: 28,200,000
Industry: GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC
Exchange: XNAS

Here’s a list of headlines for Ekso Bionics:

Today 04:30PM - Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 Conference Call to Follow
Apr-23-25 08:16AM - Bionic P&O Chosen as First Distributor of Ekso Indego Personal Within the Orthotics & Prosthetics Industry
Mar-04-25 02:03AM - Ekso Bionics Holdings Inc (EKSO) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...
Mar-03-25 04:17PM - Ekso Bionics: Q4 Earnings Snapshot
Mar-03-25 04:17PM 04:05PM - Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results
Feb-24-25 04:30PM - Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 Conference Call to Follow
Feb-10-25 07:00AM - NSM Named Exclusive Distributor of Ekso Indego Personal Within the CRT Industry
Jan-13-25 08:00AM - Ekso Bionics Reports Certain Preliminary Fourth Quarter 2024 Financial Results
Nov-18-24 08:04AM - Ekso Bionics to Showcase Its Device Technology in 'AI for Good' Webinar on Tuesday, November 19
Nov-12-24 08:00AM - Ekso Bionics to Participate at the 15th Annual Craig-Hallum Alpha Select Conference
Oct-29-24 06:06AM - Q3 2024 Ekso Bionics Holdings Inc Earnings Call
Oct-29-24 06:06AM 03:04AM - Ekso Bionics Holdings Inc (EKSO) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...
Oct-28-24 05:25PM - Ekso Bionics (EKSO) Reports Q3 Loss, Misses Revenue Estimates
Oct-28-24 05:25PM 04:21PM - Ekso Bionics: Q3 Earnings Snapshot
Oct-28-24 05:25PM 04:05PM - Ekso Bionics Announces Third Quarter 2024 Financial Results
Oct-21-24 08:00AM - Ekso Bionics to Report Third Quarter 2024 Financial Results on October 28, 2024
Aug-29-24 10:42PM - Ekso Bionics Announces Pricing of $6.0 Million Underwritten Public Offering
Aug-26-24 10:58AM - Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update
Aug-20-24 08:00AM - Ekso Bionics Announces Receipt of Initial CMS Reimbursement for Ekso Indego Personal
Jul-30-24 10:28AM - Q2 2024 Ekso Bionics Holdings Inc Earnings Call
Jul-29-24 04:47PM - Ekso Bionics: Q2 Earnings Snapshot
Jul-29-24 04:47PM 04:05PM - Ekso Bionics Reports Record Quarterly Sales of $5.0 Million in Second Quarter 2024

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-25T15:00:00Z - Construction Robots Market to Expand from USD 1.15 Billion in 2023 to USD 4.10 Billion by 2032 at a CAGR of 15.18% | Research by SNS Insider
B2 - 2025-02-21T15:00:00Z - Rehabilitation Robots Market Size Expected to Reach USD 1776.24 Mn by 2034
B3 - 2025-02-10T12:00:00Z - NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry
B4 - 2025-01-30T09:30:00Z - Gait Trainer Market Set to Grow from USD 395.6 Million in 2025 to USD 637.8 Million by 2035 at a 4.9% of CAGR, Driven by Advanced Technologies | Future Market Insights, Inc.
B5 - 2024-11-25T13:00:00Z - Rehabilitation Robots Market Analysis Report 2025-2030, Featuring Profiles of Tyromotion, Hocoma, Rex Bionics, Kinova, Rehab-Robotics, ReWalk Robotics, Ekso Bionics, Cyberdyne and Bionik Laboratories
B6 - 2024-11-12T13:00:00Z - Ekso Bionics to Participate at the 15th Annual Craig-Hallum Alpha Select Conference

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Ekso Bionics (EKSO).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

EKSO_OUT_3 [2025-04-28 19:06:55 -0400] 1004 Bytes | 294 tokens | Cum: 1751 tkns (21.89% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T20:44:29Z - Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 - Conference Call to Follow...
A2 - 2025-04-28T20:44:25Z - Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting...
A3 - 2025-04-28T20:30:00Z - Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 - Conference Call to Follow - E...
A4 - 2025-04-28T20:43:35Z - Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 - Conference Call to Follow | T...
A5 - 2025-04-28T20:42:48Z - Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 - Conference Call to Follow...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

EKSO_OUT_5 [2025-04-28 19:06:55 -0400] 1181 Bytes | 339 tokens | Cum: 2092 tkns (26.15% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 - Conference Call to Follow**Date: 2025-04-28Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/29/tmt-newswire/globenewswire/ekso-bionics-to-report-first-quarter-2025-financial-results-on-may-5-conference-call-to-follow/2101028Phoenix Asia Holdings Limited Announces Closing of Its Initial Public Offering

SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EKSO_OUT_7 [2025-04-28 19:06:56 -0400] 1183 Bytes | 265 tokens | Cum: 2359 tkns (29.49% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): results and discuss recent business developments.

To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.eksobionics.com under "Presentations & Events" in the Investors section.

About Ekso Bionics®

Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EKSO_OUT_9 [2025-04-28 19:06:56 -0400] 841 Bytes | 206 tokens | Cum: 2567 tkns (32.09% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO." For more information, visit: www.eksobionics.com.

Contact:

Get the latest news

delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

Stephen Kilmer

Investor Relations

Advertisement

Direct: (646) 274-3580

Email: [email protected]

Advertisement

Advertisement

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EKSO_OUT_11 [2025-04-28 19:06:58 -0400] 1084 Bytes | 292 tokens | Cum: 2861 tkns (35.76% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-03-17 8-K Item 1.01

Entry into a Material Definitive Agrmt.

On March 17, 2025, Ekso Bionics Holdings, Inc. (the Company) entered into a warrant inducement agreement (the Inducement Agrmt) with an existing holder (the Investor) of the Companys Series A Warrants and Series B Warr...

S5 - 2025-03-03 10-K Item 7. MGT'S DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations together with the CONS financial statements and the related notes in...

S6 - 2025-03-03 8-K Item 2.02 Results of Oper and Fin Cond

On March 3, 2025, Ekso Bionics Holdings, Inc. (the Company) reported its financial results for the three and twelve months ended December 31, 2024. The full text of the press release announcing such results is attached as ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

EKSO_OUT_13 [2025-04-28 19:06:59 -0400] 1181 Bytes | 292 tokens | Cum: 3155 tkns (39.44% of 8k)
==========================================================================

Showing S4 (chunk 1 of 6): S4:
Item 1.01

Entry into a Material Definitive Agreement.

On March 17, 2025, Ekso Bionics Holdings, Inc. (the Company) entered into a warrant inducement agreement (the Inducement Agreement) with an existing holder (the Investor) of the Companys Series A Warrants and Series B Warrants (collectively, the Existing Investor Warrants) that the Company previously issued as part of a public offering by the Company (the Public Offering), pursuant to which, among other things, the Investor agreed to exercise for cash all of its Existing Investor Warrants to purchase an aggregate of 9,800,000 shares (the Existing Investor Warrant Shares) of the Companys common stock, par value $0.001 per share (the Common Stock), at a reduced exercise price of $0.4239 per share (the Inducement Exercise). In consideration for exercising the Existing Investor Warrants, the Company agreed to issue to the Investor

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EKSO_OUT_15 [2025-04-28 19:06:59 -0400] 1181 Bytes | 273 tokens | Cum: 3430 tkns (42.88% of 8k)
==========================================================================

Showing S4 (chunk 2 of 6): a new Common Stock Purchase Warrant, to purchase up to an aggregate of 10,500,000 shares of Common Stock (such warrants, the Inducement Warrant and such shares of Common Stock issuable upon exercise thereof, the Inducement Warrant Shares). The Inducement Warrant, which was issued in conjunction with the entrance into the Inducement Agreement, will become exercisable upon the date the Company receives approval of the Companys stockholders (the Stockholder Approval Date) in accordance with the applicable rules and regulations of The Nasdaq Capital Market, and may be exercised following such date through the five (5) year anniversary of the Stockholder Approval Date, at an exercise price of $0.4239 per share.

In the event any exercise of the Existing Investor Warrants would otherwise cause the Investor to exceed a beneficial ownership, limitation equal to 4.99% of the number of shares of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EKSO_OUT_17 [2025-04-28 19:07:00 -0400] 1181 Bytes | 251 tokens | Cum: 3683 tkns (46.04% of 8k)
==========================================================================

Showing S4 (chunk 3 of 6): Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of the Existing Investor Warrants (the Existing Warrant Beneficial Ownership Limitation), the Company shall only issue such number of shares of Common Stock permitted under the Existing Warrant Beneficial Ownership Limitation, as directed by the Investor, with the balance of the Existing Investor Warrant Shares to be held in abeyance until notice from the Investor that the balance (or portion thereof) may be issued in compliance with the Existing Warrant Beneficial Ownership Limitation. The portion of Existing Investor Warrants held in abeyance shall be deemed prepaid and exercised (provided no additional exercise price shall be payable) in accordance with the Inducement Agreement.

Under the Inducement Warrant, the Company is obligated to seek stockholder approval fo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EKSO_OUT_19 [2025-04-28 19:07:00 -0400] 1181 Bytes | 284 tokens | Cum: 3969 tkns (49.61% of 8k)
==========================================================================

Showing S4 (chunk 4 of 6): r the exercise of the Inducement Warrant at either an annual or special meeting of stockholders to be held on or prior to July 15, 2025. The Company also agreed, subject to certain exceptions, not to issue any shares of Common Stock or Common Stock equivalents until May, 31, 2025 or enter into or effect Variable Rate Transaction (as defined in the Inducement Agreement) until September 13, 2025.

The issuance of the Existing Investor Warrant Shares was registered as part of the Public Offering pursuant to a Registration Statement on Form S-1 (File No. 333-281081), which was declared effective by the Securities and Exchange Commission (the SEC) on August 29, 2024 (the Registration Statement).

The Inducement Warrant, and the Inducement Warrant Shares underlying the Inducement Warrant, were issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EKSO_OUT_21 [2025-04-28 19:07:01 -0400] 1181 Bytes | 276 tokens | Cum: 4247 tkns (53.09% of 8k)
==========================================================================

Showing S4 (chunk 5 of 6): amended (the Securities Act), contained in Section 4(a)(2) thereof.

Each Inducement Warrant is exercisable at a price per share of Common Stock of $0.4239. Upon obtaining stockholder approval, each Inducement Warrant will become immediately exercisable. The exercise price of the Inducement Warrant is subject to appropriate adjustment in the event of stock dividends, stock splits, stock combinations, reorganizations or similar events affecting the Common Stock. Subject to limited exceptions, the holder of the Inducement Warrant will not have the right to exercise any portion of its Inducement Warrant if the holder (together with such holders affiliates, and any persons acting as a group together with the holder or any of the holders affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, upon election by the holder prior to the issuance of any Warran

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EKSO_OUT_23 [2025-04-28 19:07:02 -0400] 790 Bytes | 194 tokens | Cum: 4443 tkns (55.54% of 8k)
==========================================================================

Showing S4 (chunk 6 of 6): ts, 9.99%) of the shares of Common Stock then outstanding. At the holders option, upon notice to the Company, the holder may increase or decrease this beneficial ownership limitation not to exceed 9.99% of the shares of Common Stock then outstanding, with any such increase becoming effective upon 61 days prior notice to the Company.

In addition, the Company is obligated to file a registration statement on Form S-3 (or Form S-1 or other appropriate form if the Company is not then S-3 eligible) no la...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

EKSO_OUT_25 [2025-04-28 19:07:08 -0400] 6367 Bytes | 1770 tokens | Cum: 6215 tkns (77.69% of 8k)
==========================================================================

This is our set of metrics for Ekso Bionics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-----------------------+
| Volume: 591,531 | Perf Month: 15.91% | Option/Short: Yes / Yes | Sales Y/Y TTM: -1.94% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 219.43K | Perf Quarter: -18.90% | Short Float: 1.61% | ROE: -89.52% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 2.70 | Index: - | Short Ratio: 1.99 | ROI: -66.60% |
+---------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 67.00 | Market Cap: 14.76M | Short Interest: 0.44M | Sales Surprise: 0.79% |
+---------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.04 | Shs Outstand: 29.02M | Beta: 1.10 | EPS Surprise: -75.00% |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 25.24% | Shs Float: 27.07M | Sales Q/Q: 5.01% | P/E: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA50: 13.85% | Inst Own: 14.25% | Sales past 5Y: 8.98% | Earnings: Mar 03 AMC |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -35.74% | Insider Own: 6.72% | Employees: 61 | |
+---------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 24.57% | Insider Trans: 0.00% | Debt/Eq: 0.47 | |
+---------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Ekso Bionics officers or majority shareholders (if available).

Inside Trans: EKSO BIONICS HOLDINGS, INC. (EKSO) by Davis Scott G. (CEO) on 2025-03-14
- Common Stock: 5590 shares at $N/A (I)

Inside Trans: EKSO BIONICS HOLDINGS, INC. (EKSO) by Jones Jason C (Chief Operating Officer) on 2025-03-14
- Common Stock: 24248 shares at $N/A (I)

Inside Trans: EKSO BIONICS HOLDINGS, INC. (EKSO) by Wong Jerome (Chief Financial Officer) on 2025-03-14
- Common Stock: 24248 shares at $N/A (I)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 18160000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -12424000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.5085
Average Volume: 133325.4
30-Day High: 0.5085
30-Day Low: 0.361

[Detailed Financials: Q2 2024]
- Total Assets: $26,984,000.00
- Total Liabilities: $14,925,000.00
- Total Equity: $12,059,000.00
- Current Assets: $18,642,000.00
- Current Liabilities: $7,704,000.00

[Income Statement: Q2 2024]
- Revenue: $4,950,000.00
- Net Income: $-2,416,000.00
- Gross Profit: $2,637,000.00
- Operating Income: $-2,335,000.00
- Earnings Per Share (EPS): -0.13

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-2,914,000.00

[Detailed Financials: Q1 2024]
- Total Assets: $28,957,000.00
- Total Liabilities: $14,906,000.00
- Total Equity: $14,051,000.00
- Current Assets: $20,516,000.00
- Current Liabilities: $7,312,000.00

[Income Statement: Q1 2024]
- Revenue: $3,756,000.00
- Net Income: $-3,429,000.00
- Gross Profit: $1,951,000.00
- Operating Income: $-3,256,000.00
- Earnings Per Share (EPS): -0.2

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $161,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Ekso Bionics (EKSO).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Ekso Bionics.

2) MARKET_SCORE[]
This conversation was initiated because EKSO is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for EKSO.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, EKSO could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect EKSO to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Ekso Bionics.

11) ETHICAL_RATING[]
Rate Ekso Bionics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Ekso Bionics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

EKSO_IN_27 [2025-04-28 19:07:08 -0400] 126 Bytes | 29 tokens | Cum: 6457 tkns (80.71% of 8k)
==========================================================================

====================================
[2025-04-28 19:07:08] # Analysis Completed
Elapsed Time: 17.17 seconds